Di Nicolantonio R, Morgan T O
Clin Exp Hypertens A. 1987;9(1):19-32. doi: 10.3109/10641968709160028.
Atrial Natriuretic Peptide (ANP) exerts a potent diuretic and natriuretic action in rat, dog and man. To test whether these actions of ANP are due to antagonism of the antinatriuretic actions of endogenous angiotensin II, an examination was made of the renal actions of ANP in anesthetized rats with and without captopril pretreatment. Captopril treatment did not alter the diuretic and natriuretic action of a single, intravenous bolus injection of ANP (1000 ng of the 8-33 ANP). Captopril treatment did significantly attenuate the diuretic and natriuretic actions of Furosemide (20 mg/kg ip). This attenuation was not reversed by concomitant, exogenous angiotensin II infusion. These results suggest that while ANP exerts its renal actions independently of the circulating renin-angiotensin system the diuretic and natriuretic action of Furosemide is modulated by a substrate of angiotensin converting enzyme.
心房利钠肽（ANP）在大鼠、狗和人类中发挥强大的利尿和利钠作用。为了测试ANP的这些作用是否归因于对内源性血管紧张素II的抗利钠作用的拮抗，研究了在有或没有卡托普利预处理的麻醉大鼠中ANP的肾脏作用。卡托普利治疗并未改变单次静脉推注ANP（1000 ng的8-33 ANP）的利尿和利钠作用。卡托普利治疗确实显著减弱了呋塞米（20 mg/kg腹腔注射）的利尿和利钠作用。这种减弱并未因同时输注外源性血管紧张素II而逆转。这些结果表明，虽然ANP独立于循环肾素-血管紧张素系统发挥其肾脏作用，但呋塞米的利尿和利钠作用受血管紧张素转换酶底物的调节。
